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Objectives: Equity is one of the founding principles in most healthcare systems. Financial constraints entail an increased risk of exacerbating inequities and a greater need for
evidence-based decisions. It is, therefore, both important and timely to enquire how equity can be addressed in health technology assessment (HTA) practice. We aimed to explore
related practices from a broad range of HTA agencies, identify exemplary approaches and common concerns, and offer insights for future considerations.
Methods: HTA agencies for which both methodological guides and HTA reports were publicly available were selected from an initial comprehensive pool. Information was extracted
on issues ranging from a general commitment to fairness to specific measures targeting both methodological and process-related elements.
Results: Methodological documents and ninety-eight reports from nineteen agencies were analyzed. Our findings indicate that equity was not a standard consideration in HTA report
production. The nature of specific approaches and the amount of resources invested into including an equity perspective varied considerably. Specific measures (e.g., appropriate
information sources, analytical tools, and schemes) were mentioned by almost half of the agencies analyzed. Albeit sporadic, both horizontal and vertical equity considerations were
identified in included HTA reports.
Conclusions: While varying legal contexts and institutional principles can lead to different interpretations of equity at the decision point, a combination of methodological and
process-related practices could contribute to more equity-sensitive evaluations, especially in conjunction with enhanced dissemination of existing methodological tools. Networking
initiatives on behalf of existing collaborating platforms could play an important role in this direction.
Keywords: Equity, Health technology assessment, Inequities, Agency approaches
Recent economic developments at the global level have led to
both an increased focus on evidence-based approaches for ra-
tional policy making in health care and exacerbated inequities
across social determinants of health. While a given health pol-
icy, health program, or coverage decision may have no direct
impact on inequities, it may also reduce or intensify them.
Health technology assessment (HTA) was conceived as a tool
to guide decision makers in efficiently allocating limited re-
sources within the health system and enabling timely access
to appropriate technologies based on scientific knowledge. It
is one of the main evidence-based tools informing coverage
decisions in many countries. Furthermore, it was endorsed by
the World Health Organization (WHO) in May 2014 as a vital
component of decision making for countries aiming to achieve
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universal coverage in an equitable way (1). It is, therefore, im-
portant to consider whether HTA practice is concerned with
equity questions and how such concerns could be incorporated
in the development of assessments in a realistic way.
The literature on equality and equity in health and health
care is vast and multifaceted. In her defining work for WHO,
Whitehead (2) states that the term inequity goes beyondmeasur-
able differences in health status to include a moral and ethical
dimension; inequities are differences that are unnecessary and
avoidable but are also considered unfair and unjust in the given
context. Equity is “therefore concerned with creating equal
opportunities for health and with bringing health differentials
down to the lowest level possible” (2). TheWHO’s Commission
on Social Determinants of Health (CSDH) further specified that
systematic differences in health considered to be avoidable by
reasonable action are unfair and thus inequitable (3).
Evans and Brown (4) first proposed the operationalization
of determinants across which such differences can exist with the
PROGRESS acronym, later to be extended to PROGRESS-Plus
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(Place of residence, Race/ethnicity, Occupation, Gender, Reli-
gion, Education, Socioeconomic status, Social capital; “Plus”
includes additional elements that influence health equity such as
age, sexual orientation, disability and other vulnerabilities) (5).
The “community effectiveness” of a given technology, namely
its impact when applied in a “real world” setting compared
with the experimental environment of a clinical trial, may vary
for different population groups as it takes into account contex-
tual factors (6). Thus, to assess the real world consequences of
adopting a given health technology, contextual elements need
to be considered and the corresponding evidence sources and
types included in evaluations (7–10).
TheHTAGlossary (HTAglossary.net) defines equity as “the
fair allocation of resources or treatments among different indi-
viduals or groups, such that they each get what they are owed
or what they are entitled to. ( . . . ) Vertical equity means that
the people in the greatest need of services receive the most
services, and horizontal equity means that people who have
similar needs receive similar services.” In the context of HTA
for resource allocation, there has been ample discussion on eq-
uity concerns at the decision point, both at the theoretical level,
for example, on value judgments and the underlying theories
of distributive justice, and from a methodological perspective.
Williams and Cookson’s (11) estimate in 2006 was that the ma-
jority of HTA programs did not have a systematized approach
toward balancing equity concerns with efficiency considera-
tions when determining value. Culyer and Bombard (12) note
that to date, equity discourse among HTA agencies takes the
form of either a general awareness and recognition of relevant
issues, such as the differentiation between horizontal and verti-
cal equity, or more concrete individual approaches, such as the
application of equity weights in the evaluation of benefits and
costs.
When it comes to evidence assessment, best practice ap-
proaches have long recognized the importance of considering
sociocultural elements along with clinical effectiveness, safety,
and costs. However, these elements have not been sufficiently
incorporated in practice, mainly due to restrictions in time and
other resources (13). Several important initiatives emerged in
recent years, going beyond the general consideration of socio-
cultural elements to explicitly address equity issues related to
HTA. The WHO Collaborating Centre for Knowledge Transla-
tion and Health Technology Assessment in Health Equity put
together the first “equity-oriented toolkit” for HTA (14), while
Culyer and Bombard developed a framework on equity-related
issues to be considered by decision makers across the spectrum
of HTA report production (12). Furthermore, extensive method-
ological work on incorporating equity considerations exists for
individual HTA domains, such as on systematic reviews of ef-
fectiveness (10;15;16) or economic evaluation (17–19).
Perhaps most notable in this respect is the work of the
Campbell and Cochrane Equity Methods Group. The Group
responded to the CSDH endorsement of systematic reviews as
one of the tools that could be used to guide political action on
equity (20) by launching a comprehensive research effort to op-
timize existingmethods. It evaluated the incorporation of equity
concerns in existing reviews and found that their consideration
was sporadic, variable, and inadequate (21;22). Subsequently,
they produced concrete signposts for equity-sensitive reviews,
including an equity extension for the PRISMA reporting tool
(15;16;23).
While equity is an important criterion from the decision-
makers’ point of view (24), evidence used to inform pol-
icy does not always take relevant considerations into account
(19;21;25;26). Very little information exists on institutional
practices toward equity-related issues in HTA report produc-
tion (25;27;28). Our research aimed to systematically explore
whether and how HTA agencies include equity considerations
in their assessments; furthermore, to map approaches, both
methodological and process related, that could accommodate
equity-sensitive reports even if they are not initially adopted for
that purpose; lastly, to illustrate exemplary practices in combi-
nation with methodological literature that could aid those in-
terested in including equity elements in their work. We were
not concerned with the equity discussion on theories of dis-
tributive justice adopted by individual agencies, as reflected, for
example, in the setting of cost-effectiveness thresholds or the
rationale behind equity weights, as these are bound to be both
institution- and context specific (12).
METHODS
Composition of the Agency Pool
We used a systematic, iterative approach to identify interna-
tional agencies involved inHTAproduction. Aiming for a broad,
comprehensive sample we combined the membership lists of
the International Network of Agencies for Health Technol-
ogy Assessment (INAHTA), the European Network for Health
Technology Assessment (EUnetHTA) and nonprofit members
of Health Technology Assessment International (HTAi) with
agencies included in comparative analyses published in the In-
ternational Journal of Technology Assessment in Health Care
in 2009 and 2010.
Only agencies actively involved in HTA production (by
commissioning or conducting assessments), for which both a
methodological guide and at least one HTA report were publicly
available, were considered for the analysis. To obtain this
information, we searched all agency Web sites in January and
February 2011. We subsequently contacted agencies by email
to verify the validity of retrieved information and documents,
unless (a) it was clear from their Web site that they were not
actively involved in HTA or (b) online information available
in the working languages (English, French, or German) was
insufficient.
315 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 31:5, 2015
https://doi.org/10.1017/S0266462315000549
Downloaded from https://www.cambridge.org/core. Universitaetsbibliothek, on 26 Oct 2017 at 13:48:22, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Panteli et al.
Document Selection
Documents were included as methodological guides if they
had been developed by the respective agency and described
the methodological approach on which assessments were to
be based. Documents had to cover at least the assessment of
effectiveness for drugs, nondrug or population-based interven-
tions. Thus, documents only covering cost-effectiveness or not
describing evidence procurement were excluded. Where more
methodological documents with different scopes were available
from each agency (e.g., guide for assessment and template for
manufacturer submissions), these were included if correspond-
ing, publicly available HTA reports were also included. The
most recent version available at the time of document selection
was included for agencies where consecutive iterations of the
same guide existed.
Full HTA reports from included agencies were considered
for analysis if they assessed a therapeutic (drug or nondrug) or
population-based intervention in a systematic way, that is by (a)
including a search for evidence in at least two sources and (b)
considering primary research and not exclusively synthetized
evidence. Aiming to capture practices as current as possible at
the time of selection, the three most recent reports for each cat-
egory were identified and no reports published before January
2006 were included. Reports commissioned by other agencies
included in the sample as well as draft versions were excluded.
To facilitate a simpler analysis, where more than one type of
report was available (e.g., single and multiple appraisals by the
National Institute for Health and Care Excellence), we restricted
our sample to one type of document.
Information Extraction and Analysis
We aimed to explore two main questions, namely (a) the extent
to which equity considerations are an issue for agencies ac-
tively involved in HTA production and (b) what methodological
and process-related approaches are in place that could facilitate
equity-sensitive approaches. We developed separate extraction
tools for methodological papers and HTA reports, tailored to
capture this information (Supplementary Table 1).
We extracted information explicitly on equity and on ap-
proaches or processes that can potentially enable the exploration
of differences across population groups, such as subgroup anal-
yses or stakeholder involvement, even if they were not used by
the agency for equity purposes. While the focus was on assess-
ment, equity-related issues with regard to appraisal were also
taken into account if they were raised in the included docu-
ments (where applicable). As per the research scope, we did
not analyze model assumptions included in economic evalua-
tions; we did extract equity considerations if theywere explicitly
discussed.
The extraction tools were formulated broadly to allow for
different types and formulations of equity-related elements.
This approach was adopted based on previous research (27),
which suggested that such elementswould range from axiomatic
statements on commitment to fairness to specific methods for
research or analysis, occasionally falling under the heading of
psychosocial/sociocultural considerations. Methodological lit-
erature on equity considerations in evidence syntheses that was
available in early 2011 (9;10;14;15) also informed the develop-
ment of the extraction tools. Finally, stakeholder involvement,
to the extent it was described in included documents, was also
explored. This was based on the assumption that fairness of
procedures is important in the context of HTA (12). Further-
more, deliberative processes can provide input on the relevance
of research questions as well as on contextual factors to be
considered during the assessment—both issues that are diffi-
cult to examine by means of evidence types usually included in
assessments (29–32).
The extraction tools were piloted and subsequently op-
timized; information was extracted by one author (D.P.) and
checked by a second (J.K.); discrepancies were solved by con-
sensus. Results from methodological guides are presented in a
narrative synthesis, and descriptive statistics are provided for
HTA reports where appropriate (absolute numbers are given




Of 121 agencies identified, both methodological papers and
HTA reports in the working languages were available for nine-
teen (Supplementary Figure 1). The nineteen agencies included
in the analysis were diverse in terms of remit (some only eval-
uated pharmaceuticals or procedures while others covered a
broad range of technologies) and role in their health system (
Table 1). Due to the study’s technical limitations in terms of
access to information and language, some countries were not
represented in the sample and others were present more than
once.
Equity Considerations in Methodological Guides
As a natural consequence of the variability of agencies included
in the sample, methodological guides included general educa-
tional handbooks (e.g., DACEHTA), agencymethods for assess-
ment only (e.g., AHRQ, DIMDI), agency methods for assess-
ment and appraisal (e.g., G-BA, TLV) and specific templates
outlining requirements for submissions by the industry (e.g.,
DERP) (Table 1). Furthermore, documents varied in terms of
length and age at the time of analysis; while some agencies
indicated having newer, internal manuals available at the time
in their responses, our research only included the latest pub-
licly available documents in the analysis. A full list of included
methodological guides can be found in Supplementary Table 2.
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Table 1. Agencies Included in the Analysis, Type of Methodological Guide and Number of Included Reports
No. of included reports
Type of methodological Population-based
Agency Country guide Drug Nondrug intervention
Agency for Healthcare Research and Quality (AHRQ) US 2 (2011) 3 3 0
Australian Safety and Efficacy Register of New Interventional Procedures - Surgical (ASERNIP-S) AU 3 (2003) 0 3 0
1 (2008)
Canadian Agency for Drugs and Technologies in Health (CADTH) CA 2 (2003 & 2011) 3 3 3
Center for Reviews and Dissemination (CRD) UK 1 (2009) 3 3 3
Danish Centre for Health Technology Assessment (DACEHTA) DK 1 (2007) 1 0 0
Drug Effectiveness Review Project (DERP) US 2 (2010) 3 0 0
4 (2010)
German Institute for Medical Documentation and Information (DIMDI) DE 2 (2008) 3 3 3
Federal Joint Committee (G-BA) DE 3 (2011) a 3 3 3
Gesundheit O¨sterreich (GO¨G) AT 2 (2010) 0 1 2
Haute Authorite´ de Sante´ (HAS) FR 2 (2000) 0 3 3
Health Intervention and Technology Assessment Program (HITAP) TL 1 (2009) 0 0 1
Federal Association of Health Insurers (HVB) AT 2 (2008) 1 3 1
Institute for Quality and Efficiency in Health Care (IQWiG) DE 2 (2011) 3 3 3
Belgian Health Care Knowledge Centre (KCE) BE 2 (2007) 1 3 3
Ludwig-Boltzmann Institute (LBI) AT 2 (2008) 2 3 1
Medical Services Advisory Committee (MSAC) AU 3/4 (2005)b 0 3 0
National Institute for Health and Clinical Excellence (NICE) UK 3 (2004, 2008, 2009) 3 3 0
Pharmaceutical Management Agency (PHARMAC) NZ 4 (2010) 1 0 0
Dental and Pharmaceutical Benefits Agency (TLV) SE 3 (2008) 3 0 0
Subtotals 33 40 26
Total 98c
Note. 1, general methods; 2, agency methods for assessment only; 3, agency methods for assessment and appraisal; 4, guide for submission by the industry.
a Document has legal function.
b Appraisal process is described only for the “interim funding” approach, which falls under the “coverage with evidence development” scope.
c One report addressed both a drug and a non-drug intervention and is counted twice in the subtotals.
Approximately half of the methodological documents in-
cluded some interpretation of equity among the goals of the
respective health technology assessment program or the doc-
ument itself. In this context, this took the form of “fairness”
(AHRQ), “social justice” (KCE), the “appropriate considera-
tion of the interests of those afflicted, taking into account age,
biological and social gender and particularities related to life
circumstances” (G-BA) or “equity” verbatim (CRD, MSAC,
NICE). These formulations were related to the agency’s remit
and the type of document examined. For example, the G-BA is
responsible for decision making on health technologies in the
German statutory health insurance system and its methods are
described in its code of procedure (“Verfahrensordnung”). It
was, therefore, not surprising that the latter included a consid-
eration of different population characteristics to be taken into
account. On the other hand, methodological guides purely fo-
cusing on assessment elements (e.g., HVB, DIMDI) did not
necessarily require the description of system-level goals.
Methodological Elements. As a general approach potentially related
to equity concerns, the consideration of (psycho)social issues
related to the adoption of the technology in question was men-
tioned by several agencies (CADTH, DIMDI, GO¨G, KCE,
NICE). CADTH mentioned such elements under the concept
of “intangible” factors that need to be accounted for and can
include “patient satisfaction, individual acceptance of screen-
ing/treatment, stigmatization/anxiety and gender/family con-
cerns” and distinguished them from issues that need to be con-
sidered under “equity-efficiency trade-offs,” which were men-
tioned in a separate subsection. According to the KCE, patient
preferences were to be examined in the societal context, espe-
cially in case of social justice concerns.
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Determinants in the PROGRESS-Plus acronym were ex-
plicitly mentioned in three ways across the included method-
ological guides: (a) to consider in terms of relevance of different
subgroups when formulating the research questions (AHRQ,
DERP, G-BA), (b) in terms of looking for or conducting
subgroup analyses in included studies on effectiveness (AHRQ,
CADTH, DERP), and (c) recognizing groups to examine more
closely in the context of inequalities (CADTH, CRD, GO¨G,
IQWiG, NICE).
Table 2 shows specific approaches adopted by individual
agencies thatwere related either to general equity considerations
or the examination of effects on population subgroups. These
range from the appropriate sources for evidence on psychosocial
implications (DIMDI) to individual tools such as health services
impact (CADTH) and the NICE Equality Scheme.
Process-Related Elements. Information on practices related to proce-
dural equity, such as the participation of stakeholders, was ex-
tracted where available. However, the depiction of such issues
was highly dependent on the nature of the methodological guide
under consideration. Thus, the compiled overview of related
processes is potentially incomplete both for individual agencies
and the overall sample.
Examples of approaches described in the documents in-
cluded the involvement of stakeholders in topic selection
(AHRQ); opening the assessment protocol to public com-
ment before embarking on the actual assessment process
(IQWiG); public consultation processes on draft assessment
reports (AHRQ, DERP, IQWiG); open review rounds upon pub-
lication of the report (KCE); and interaction with a body acting
as a permanent advisor throughout the appraisal process (NICE
Citizens Council).
Equity was mentioned as a contributing factor for topic
selection in the documents of five institutions (AHRQ, DERP,
G-BA, MSAC, PHARMAC). While in most cases this was kept
general to include vulnerable groups and patient subgroups,
PHARMAC explicitly mentioned advancing the health of the
Maori/Pacific population in New Zealand as a prioritization
criterion for assessments.
Evidence from HTA Reports
We identified ninety-eight reports from agencies included in the
analysis, spanning drug, nondrug and population-based inter-
ventions (Table 1) and published between 2006 and 2011. In-
formation on the prespecified domains was extracted and trans-
ferred to extraction tables (one report which addressed both
drug and nondrug interventions was extracted twice).
As per the inclusion criteria, all reports included an as-
sessment of effectiveness, while fifty-one reports (52 percent)
also considered economic elements. Of those, twenty-six (51
percent) reported original economic evaluations based on a va-
riety of methods, sixteen (31 percent) presented and discussed
the results of existing economic studies, while a further nine
(18 percent) provided information on direct costs with varying
sources and level of detail.
Some agencies (DERP, TLV, G-BA, IQWiG for screening
interventions) mention in their reports a general commitment
to producing assessments that consider equity or fairness. Only
one report had a term (“social inequalities”) related to equity
in the topic. This report adopted a clear equity focus and “ap-
plied an ‘equity lens’ to tobacco control policies, re-examining
the available evidence about the impact of policy measures and
other population-level interventions to assess their role in tack-
ling health inequalities ( . . . )” in a systematic way (33). Six re-
ports included some element of equity in their objectives, three
of which were concerned with addressing the issue of unequal
access (due to regional or socioeconomic factors) and a further
two with reducing inequalities in health (see Supplementary
Table 3).
Methodological Elements. Nineteen reports (19 percent) included the
consideration of population subgroups among their research
questions. However, only five of those did so with an ex-
plicit link to contextual or socioeconomic elements or ac-
cess to care while the rest were interested in the appli-
cability of clinical effectiveness findings across population
groups. Similarly, subgroup analyses were carried out or
reported mainly to test the applicability of clinical find-
ings for different groups of patients and not in relation to
community effectiveness. Only seven reports included their
own subgroup analyses, while thirteen (13 percent) pointed
out that subgroup analyses were not possible based on the
available primary research and thirteen (13 percent) reported
subgroup analyses from individual primary studies. The deter-
minants most frequently considered were age, gender, comor-
bidities and disease severity (in descending order). The dearth of
evidence on specific populations (such as breastfeeding moth-
ers of low socioeconomic status, migrant populations, etc.) was
particularly highlighted by three reports with increased rele-
vance for vulnerable groups, who are underrepresented among
study participants.
Ten reports (10 percent) considered ethical and sociocul-
tural elements separately as one of their assessment domains;
of those, half did not succeed in finding any primary evidence
to match the corresponding research questions. Three more re-
ports mentioned that while such issues are important, they were
beyond the scope of the presented document. Only one report
involved a participatory approach with patients and their fam-
ilies to obtain relevant information to contextualize findings
from published research.
Interpretation of Results and Recommendations in Included Reports. Eighteen re-
ports (18 percent) included equity considerations in their inter-
pretation of results (see Supplementary Table 3). These con-
siderations encompassed elements of coverage (e.g., technol-
ogy not covered or only covered by some regional plans in a
decentralized context or high copayments putting low-income
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Table 2. Specific Methods Related to Health Equity
AHRQ -Population and clinical subgroups considered at the topic development stage
-Subgroup analyses or meta-regression to test for effect of specific characteristics (e.g., age, gender) in the body of studies
CADTH -Subgroup analyses mentioned as analytical tool for clinical review and economic evaluation
-Guiding principles of equity-efficiency trade-offs (identify groups the intervention is likely to benefit and impact; identify impact on cost and outcomes for persons
not using the technology; consider differing cost-effectiveness results by subgroup; consider other equity implications in the analysis or additionally, examples
provided including differential access, unmet need, rule of rescue)
-Health Services Impact on health equity as additional domain
CRD -Concrete tools to examine the influence of patient-level characteristics (determinants): subgroup analyses, meta-regression or modelling when sufficient primary
information is available; exploring differential outcomes by levels of disadvantage for public health interventions
-For reviews with equity-focus or that depict differences in groups: methods combining graphic and narrative elements for synthesis
DACEHTA As an administrational/managerial tool: does the chosen combination of technology and management model support objectives of equal access to technology?
DERP -To consider during the formulation of research questions: does effectiveness/harms vary by population subgroup based on demographics, socioeconomic status,
comorbidities, co-medication
-Subgroup analyses and meta-regression can be used to test for differences between groups in pooled analyses
DIMDI Hand search required to identify sources for psychosocial elements (usual databases not sufficient)
G-BA In the assessment of manufacturer submissions: consider specific population characteristics along the lines of age, gender, position in life, disability and chronic
conditions
GO¨G -Matrix for exploring sociocultural elements incorporating stakeholder groups and different types of elements (psychosocial, ethical, legal, organizational)
-Key questions to consider in this respect: distributive justice, i.e., does investing in the technology draw resources that will be missed elsewhere; are there social
barriers to access; influence on inter-generational relations; shift in values (meaning of sick/healthy, vulnerable groups, etc.)
IQWiG -If differentials across determinants are known/identified in advance, look for/perform pre-specified subgroup analyses
-Always examine applicability of results according to age and gender
KCE -Literature sources on patient perspective include Sociological Abstracts, PsycInfo, Embase, Medline; often additional sources may be required, such as patient
organization websites
-Qualitative methodologies to appraise patient issues (e.g., literature review, interviews or focus groups, round tables)
LBI -Checklist for quality appraisal of economic evaluations: were equity assumptions clearly stated? Were relevant equity-related characteristics for subgroups identified
and described?
MSAC -Submissions need to provide tables on validity, accuracy, applicability which show indices of accuracy for relevant population subgroups
-Submissions need to clearly state if the agency is to consider issues related to access or equity (e.g., targeting at risk populations; availability or lack of alternative
options)
NICE -In regards to economic evaluation: detailed prescriptions on QALYs, their estimation and weighting; Appraisal Committee needs to consider how its judgements bear
on distributive justice
-NICE Equality Scheme
PHARMAC -Explicit focus on the health of Maori/Pacific population (also among agency goals)
groups at disadvantage), increased prevalence among vulner-
able groups that would merit targeted interventions, variable
uptake due to psychological elements connected to specific de-
terminants (e.g., the higher uptake of bariatric surgery among
women, reluctance to participate in cystic fibrosis screening for
some ethnic groups and low awareness of sudden infant death
syndrome in families with low socioeconomic status due to a
different perception of danger) and organizational aspects that
influence access to care.
Six reports on population-based interventions recom-
mended the introduction or intensification of targeted inter-
ventions for vulnerable groups in their conclusions. A further
six reports called for measures to ensure access, which took
the form of revision of coverage plans, triage strategies for
the equitable allocation of technologies, development of exist-
ing organizational structures to enable delivery and subsidies
for vulnerable groups. Four reports included general statements
endorsing a future societal perspective or universal access in
their recommendations (see Supplementary Table 3).
Process-Related Elements. Aswas the case with the analysis of method-
ological documents, the availability of information on stake-
holder involvement in included reports was variable; findings
can, therefore, only be interpreted as indicative and not as a com-
plete overview of approaches. Forty-three reports (44 percent)
mentioned stakeholder involvement at some stage of the report
production process. The most common form of involvement
described was external review of the draft report, followed by
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participation in the determination of the scope and/or research
questions before report production began. Input methods varied,
but the online publication of documents (protocols and/or draft
reports) was a common characteristic. Some institutions, like
IQWiG, followed up on written public comment to the draft re-
port with structured meetings when elements remained unclear.
Eight reports mentioned that the topic for assessment originated
in a nomination and/or prioritization process that incorporated
public involvement.
DISCUSSION
Our findings indicate that equity was not a standard considera-
tion in HTA reports. The nature of specific approaches, as well
as the amount of resources invested into including an equity
perspective, varied considerably. Where such approaches
were used, they seemed to depend on the role and remit of
the institution, its jurisdiction level, the legal context within
the health system and finally the type of technology under
consideration. For example, NICE, an institution that has long
been a proponent of addressing equality issues in the evaluation
of health technologies, launched a separate equality scheme
in 2007. The scheme aimed to put the Institute’s commitment
to fighting discrimination and fostering equal opportunities in
practice, both by ensuring fair and appropriate representation in
advisory bodies and applying a set of equity-related questions
throughout the guidance production process (34). It is unlikely
that HTA agencies with fewer resources or a narrower scope
would be able or required to establish similar approaches.
Still, an equity-sensitive approach introduced early in the
process of report production could increase the likelihood
that potential issues are not overlooked (12) and that the
appropriate questions are asked and methods of analysis used.
It would, therefore, be preferable in comparison to an additional
consideration of potential equity concerns after effectiveness
or cost-related questions have been answered.
While the consideration of equity issues in the analyzed
reports was sporadic, it encompassed both concerns of vertical
and horizontal equity: targeted interventions were endorsed by
some reports and differential outcomes or consequences for uni-
versal applications of technologies were raised in others. While
prioritizing the evaluation (and funding) of targeted interven-
tions for specific population groups to reduce health inequities
is vital, it also depends on individual agency or policy agendas.
It is important to recognize that health technologies not aimed at
bridging the equity gap still need to be addressed in an equity-
sensitive way as they may introduce, perpetuate or exacerbate
inequities that are not apparent prima vista.
An equity-sensitive approach adopted in the early stages
of assessment would mean that specific population groups that
merit attention are taken into account while formulating the
research questions, exploring the context of technology imple-
mentation, or choosing appropriate evidence types and study
designs for the assessment (9;10;15;16;23). However, methods
used in the analysis also need to reflect these steps. Our findings
show that subgroup analyses were rarely conducted by the in-
stitutions themselves. When they were discussed, it was usually
in regard to the applicability of overall findings for population
groups with different biological or clinical characteristics and
not in connection to contextual or other equity-related factors.
Analytical tools such as subgroup analyses need to be appropri-
ately applied to avoid misinterpretation (10;22;35) and require
sufficient and adequate information from primary studies. In
fact, some included reports mentioned that subgroup analyses
were not possible due to insufficient data.
Other reports in our sample concluded that more primary
research tailored to enable insights into inequities was required
in general. The issue of adequate primary studies as a pre-
requisite for equity considerations had already been raised by
Whitehead (2) and the particular necessity of good data for
equity-sensitive evaluations was further emphasized by Tug-
well and colleagues (15). While it is hoped that the promotion
and usage of equity-oriented tools developed for evidence syn-
theses will lead to corresponding initiatives in primary research
in the long-run (16), amore active endorsement would definitely
be beneficial.
Procedural equity is not only important from the viewpoint
of fair representation. Stakeholder involvement, when struc-
tured accordingly, can also contribute to pinpointing the ques-
tions to ask and what is important. This is particularly the case
when it includes those most directly affected by a technology’s
implementation, namely patients and their caregivers. The type
and entry point of involvement is expected to vary based on
agency tradition and system context (32;36). This was mirrored
by findings from included reports, which mentioned consulta-
tion and/or participation approaches. Participation in the early
stages of report production, for instance at the protocol devel-
opment stage, can be particularly useful in revealing equity is-
sues that may need to be considered throughout the assessment.
Furthermore, an inclusion of stakeholder groups and especially
patients in the agenda setting for assessments (37) can foster the
goal of evaluating technologies to address inequalities. In both
respects, existing agency approaches can be expanded or mod-
ified to enable a clearer, more direct link between stakeholders
and an equity-sensitive approach. At this point, it is important
to note that if such approaches have an additional goal of facil-
itating equity-sensitive evaluations, those included need to be
carefully selected to ensure that important perspectives are not
missed; which parties to involve has already been found to be
one of the main challenges for agencies using related processes
(31;32).
Ideally, a fully realized equity perspective in the assess-
ment of health technologies would entail a multifaceted ap-
proach spanning protocol development to dissemination and
using both equity-aware staff and inclusive stakeholder involve-
ment. However, the need for swift assessment results along with
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Figure 1. Potential equity considerations along the evaluation process.
Table 3. Examples of Equity Considerations Depicted in Figure 1
A Equity in prioritization agenda [37], e.g., AHRQ, G-BA, PHARMAC
B Definition of disadvantage; burden of disease; contextual factors (community effectiveness); appropriate outcomes and sources; study designs, measurement tools,
etc. [12, 14–16] e.g., DERP, IQWiG
C Subgroup analyses (preferably prespecified; if only reported consider robustness and interpretation [9, 10, 35]) e.g., CRD, IQWiG, MSAC
D Descriptive approaches, ICER for different subgroups, equity weighting, mathematical models, MDCA [17–19] e.g., CADTH, NICE
E Appropriate sources and study designs (e.g. DIMDI), analytical tools (e.g., GO¨G)
F Consideration of roll-out factors related to access (e.g., DACEHTA), delivery of care [12]
G Health impact assessment, additional consideration of equity-efficiency elements, e.g., CADTH
H Contextual factors, e.g. G-BA, MSAC, NICE; [12, 23, 24]
institutional biases, special claims, etc. [12]
resource considerations can hamper both the implementation of
equity-sensitive tools that are detailed and comprehensive (38)
and the elaboration of participatory mechanisms (31). Accord-
ing to their task, process, and resources, HTA agencies inter-
ested in adopting a more equity-sensitive approach may need
to choose their areas of focus. Figure 1 combines examples
of approaches identified in our analysis (institutional names)
and insight frommethodological literature (references in square
brackets in Table 3) to provide an overview of potential points
for consideration.
STRENGTHS AND LIMITATIONS
Our study provides the first comprehensive overview of equity-
related considerations found inmethodological papers and HTA
reports from a broad range of agencies at the international level.
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Our selection of agencies and reports aimed to capture insights
from different types of institutions and on a variety of technolo-
gies. However, language barriers brought about an imbalance in
the composition of the sample, as noted in the results. Further-
more, detailed information on agency practices was not always
publicly available and led tomore agencies being excluded from
the analysis. The concrete inclusion criteria of the structured ap-
proach regarding interactions of identified agencies, eliminated
additional agencies and methodological documents that might
have had interesting contributions to offer. Information pro-
vided in more recent iterations of methodological papers was
not considered. Finally, approaches that are in place but were
not described in the identified documentation are not captured in
this publication (see also Clifford, 28); despite our best efforts,
we cannot rule out the possibility that certain available informa-
tion was overlooked. To our knowledge, at the time of extraction
and analysis there were no established standards as to what is
considered an equity-sensitive approach in HTA; therefore, our
extraction tools were formulated broadly and ad hoc, potentially
subjective decisions had to be made during the extraction pro-
cess. As a result, the presented analysis is rather indicative than
definitive in nature. The same is true regarding the depiction of
approaches toward stakeholder involvement, as it is only based
on information available in analyzed documents; the consulta-
tion of published and grey literature would be required for a
more comprehensive view (31;32;36;39). Finally, the selection
of methodological papers and reports (and thus their publica-
tion date) preceded the publication of important tools (12;16);
it would, therefore, be interesting to follow-up on our findings
when sufficient time has elapsed and explore potential changes
in practice.
POLICY IMPLICATIONS AND RECOMMENDATIONS
Varying legal contexts and institutional principles can lead to
different interpretations of equity at the decision point. Over-
all, the consideration of equity-related issues was found to
be sporadic. However, a combination of methodological and
process-related practices already in place could contribute to
more equity-sensitive evaluations. Incorporating equity con-
cerns in the assessment of health technologies is important both
for universal coverage decisions and in terms of facilitating
targeted interventions. Agencies involved in the production of
HTAs can and should take action on the matter. Several policy
implications stem from this position:
1. Awareness among HTA-doers needs to be raised and
required skills (such as understanding the importance of
PROGRESS-Plus factors) need to be acquired or expanded;
2. Given that various methodological and process-related
approaches are already used by individual agencies, knowledge
exchange and collaboration could be key. Such an exchange
could be facilitated by existing collaborative platforms in HTA.
Given the nature of the topic, a more focused initiative, such
as an Interest Subgroup on Equity, could help in emphasizing
exemplary practices. Furthermore, it could aid in the dissemi-
nation and potential adaptation of existing tools to overcome the
barrier of limited resources. Such an Interest Subgroup would
be bound to intersect with existing ones, such as the ones on
Ethics and Patient Involvement;
3. Both individual agencies and a potential coordinating ini-
tiative could consider training for staff and/or stakeholders, both
on understanding equity concerns and including them into stan-
dard practice; joint training initiatives may help with feasibility
in light of resource constraints;
4. The adequacy of primary researchwill highly influence to
what extent equity concerns can be included in HTA. Agencies
and their collaborative initiatives could endorse such a research
agenda.
CONCLUSIONS
While methodological tools for the incorporation of equity con-
siderations in the assessment of health technologies exist, it is
not clear to what extent HTA agencies are aware of them or have
the resources required to implement them. In addition to initia-
tives that could potentially be adopted by individual agencies,
existing practices indicate that knowledge exchange would be
particularly beneficial. Such an exchange could be coordinated
by existing collaborative platforms or potentially, in a more
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